229 related articles for article (PubMed ID: 25754096)
1. Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Pasta DJ; Konstan MW
J Cyst Fibros; 2015 Nov; 14(6):763-9. PubMed ID: 25754096
[TBL] [Abstract][Full Text] [Related]
2. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Morris NJ; Konstan MW
J Cyst Fibros; 2016 May; 15(3):372-9. PubMed ID: 26603642
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
4. Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
Sanders DB; Zhao Q; Li Z; Farrell PM
Pediatr Pulmonol; 2017 Oct; 52(10):1268-1275. PubMed ID: 28881091
[TBL] [Abstract][Full Text] [Related]
5. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
[TBL] [Abstract][Full Text] [Related]
6. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
[No Abstract] [Full Text] [Related]
7. The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.
Cogen JD; Whitlock KB; Gibson RL; Hoffman LR; VanDevanter DR
J Cyst Fibros; 2019 Nov; 18(6):851-856. PubMed ID: 31147301
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis.
Sequeiros IM; Jarad N
Chron Respir Dis; 2012 Feb; 9(1):9-16. PubMed ID: 22308550
[TBL] [Abstract][Full Text] [Related]
9. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL
Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564
[No Abstract] [Full Text] [Related]
10. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
[No Abstract] [Full Text] [Related]
11. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
Sawicki GS; Ayyagari R; Zhang J; Signorovitch JE; Fan L; Swallow E; Latremouille-Viau D; Wu EQ; Shi L
Pediatr Pulmonol; 2013 Oct; 48(10):954-61. PubMed ID: 23255309
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations.
Sharma A; Kirkpatrick G; Chen V; Skolnik K; Hollander Z; Wilcox P; Quon BS
PLoS One; 2017; 12(2):e0171229. PubMed ID: 28178305
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Thornton CS; Caverly LJ; Kalikin LM; Carmody LA; McClellan S; LeBar W; Sanders DB; West NE; Goss CH; Flume PA; Heltshe SL; VanDevanter DR; LiPuma JJ
Ann Am Thorac Soc; 2024 Apr; 21(4):595-603. PubMed ID: 37963297
[No Abstract] [Full Text] [Related]
16. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
[No Abstract] [Full Text] [Related]
17. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Flume PA; Morris N; Konstan MW
J Cyst Fibros; 2016 Nov; 15(6):783-790. PubMed ID: 27139161
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis.
Skolnik K; Nguyen A; Somayaji R; Thornton CS; Waddell B; Surette MG; Rabin HR; Parkins MD
BMC Pulm Med; 2015 Dec; 15():161. PubMed ID: 26651825
[TBL] [Abstract][Full Text] [Related]
19. Clinical features associated with pulmonary exacerbation diagnosis in infants and young children with cystic fibrosis.
Corcoran A; Faig W; Ren CL
Pediatr Pulmonol; 2024 Apr; 59(4):874-879. PubMed ID: 38131505
[TBL] [Abstract][Full Text] [Related]
20. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL
Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
